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Introduction: The objectives of this trial were to evaluate the
activity and safety of gemcitabine carboplatin as induction therapy
in patients with locally advanced non-small cell lung cancer
Methods: Patients received two cycles of gemcitabine (1250 mg/m2
on day 1 and 8), plus carboplatin (area under the curve  5 on day
1), after which response was established. Patients received a third
course only in the case of an objective response (OR). Non-
responding patients were directly irradiated. Toxicity was as-
sessed according to the NCI-CTC version 2, radiation toxicity
was assessed according to RTOG criteria. Response evaluation
was performed according to RECIST criteria.
Results: We identified 42 patients, of whom 37 were eligible. Of
these, 51% (95% CI, 34%-68%) achieved an OR, all partial re-
sponses. No disease progression on therapy was established. Tox-
icity was mostly hematological: 35% trombocytopenia grade 3 and
4, and 40% neutropenia grade 3 and 4. No severe bleeding or
hospitalization because of febrile neutropenia occurred.
Conclusions: Gemcitabine and carboplatin administered according
to a 3-week schedule is an active and safe induction regimen.
Pending the results of a phase III study, we believe that it is a
reasonable alternative among patients for whom cisplatin-based
chemotherapy is contraindicated.
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The combination of platinum-based chemotherapy and tho-racic irradiation is considered standard therapy in patients
with unresectable locally advanced non-small cell lung can-
cer (NSCLC). In a number of randomized studies and a
meta-analysis, chemotherapy added to radiotherapy improved
survival compared with radiotherapy alone.1
Recent studies claim concurrent chemo-irradiation to
be superior to sequential therapy as it achieves higher re-
sponse rates and adds 7% on long-term survival benefit.2,3
However, the optimal chemo- and radiotherapy combination
is yet unknown, and its major drawback is its increase in
toxicity, both hematologic and non-hematologic (mucositis,
pneumonitis, and esophagitis). This is the reason that a recent
meta-analysis and the NICE guideline restrict the use of
concurrent chemo-radiotherapy to selected patients.2 Al-
though sequential therapy is not the standard of care in the
United States, it is still widely used in Europe, mainly
because of logistical reasons.
In the sequential treatment setting, response to induc-
tion chemotherapy is an important variable in qualifying for
subsequent radiotherapy.1,4 A doublet of platinum combined
with a third-generation chemotherapeutic agent is considered
to be the most active induction regimen. One of these third-
generation agents is gemcitabine. In a recent meta-analysis,
gemcitabine-containing regimens led to a better survival than
other third-generation drug combinations in patients with
advanced NSCLC.5
Because of its more favorable toxicity profile, carbo-
platin is often preferred to cisplatin.6,7 The most frequently
used regimen in the United States combines carboplatin and
paclitaxel. In a recent meta-analysis, it was concluded that
cisplatin combinations have a survival benefit compared with
carboplatin combinations in advanced NSCLC,7 but in phase
III studies in which gemcitabine-cisplatin and gemcitabine-
carboplatin were compared, no survival benefit for the cis-
platin combination could be demonstrated in advanced dis-
ease.6,8
The aim of the present study was to investigate the
activity and toxicity of the combination of carboplatin and
gemcitabine as an induction regimen for stage III NSCLC.
PATIENTS AND METHODS
The study was conducted in three Dutch hospitals in
Rotterdam (Erasmus MC, Sint Franciscus Gasthuis, and
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MCRZ) and was approved by the local ethical committees of
each participating center.
Eligible chemonaive patients had to have a histological
or cytological diagnosis of locally advanced NSCLC. In the
case of presumed stage IIIA disease, tissue confirmation of
N2 involvement was required. In the case of stage IIIB
disease, patients with N3 (excluding supraclavicular lymph-
nodes) or T4 (excluding pleural fluid) were eligible. Other
criteria were: measurable disease according to RECIST cri-
teria, age older than 18 years, World Health Organization
performance status 2 or less, adequate bone marrow reserve
(hemoglobin10 mg/dL or 6 mmol/L, white blood cell count
higher then 4.0 109/L, absolute neutrophil count 2.0 
109/L, platelet count 100  109/L), and a calculated creat-
inine clearance of at least 60 mL/min. Women of child-
bearing age were asked to use adequate contraceptive
methods.
Exclusion criteria were the presence of other malignan-
cies (previous or current), except adequately treated in situ
carcinoma of the uterine cervix or basal or squamous cell
carcinoma of the skin, or a previous malignancy more than 5
years ago without evidence of recurrence; pregnancy and/or
breast feeding; use of any investigational agent in the month
before enrolment into the study; uncontrolled infections and
signs or symptoms of metastases; a weight loss of more than
10% in the preceding 3 months.
Pretreatment evaluation included a complete medical
history and physical examination, chest radiograph and com-
puted tomographic scanning of thorax and upper abdomen,
pulmonary function testing with diffusion capacity, routine
blood sampling, urine analysis, and electrocardiogram. All
patients had to give written informed consent.
Treatment:
The treatment scheme is presented in Figure 1. Che-
motherapy consisted of two courses of gemcitabine and
carboplatin as a 21-day regimen. Gemcitabine was given at a
dosage of 1250 mg/m2 intravenously (over 30 minutes on
days 1 and 8), carboplatin at an area under the curve of 5
(intravenous in 30 minutes on day 1) after gemcitabine.
Routine anti-emetics were given according to institutional
practice. No prophylactic growth factors were allowed.
Dose adjustments were made according to the guide-
lines described in Table 1. In the case of non-hematological
toxicity grade 4, a dose reduction with 25% of both gemcit-
abine and carboplatin was performed.
After two cycles, response evaluation was performed
according to RECIST criteria. In case of a response, one more
cycle was administered before the start of thoracic radiother-
apy. In the case of stable disease or progressive disease,
patients were immediately referred for radiotherapy. Radio-
therapy was given with a radical intent. Dose was calculated
taking into account lung toxicity (V20) and estimated esoph-
agus toxicity. The interval between the start of the last
chemotherapy and the start of radiotherapy had to be at least
4 weeks and less than 6 weeks. Toxicity was assessed weekly
using the National Cancer Institute common toxicity criteria
(NCI-CTC version 2). Radiation toxicity was scored accord-
ing to RTOG criteria
Statistics:
The study was designed according to the two-step
Simon design, with a response rate of interest after two cycles
of chemotherapy of at least 70% with a type 1 error of 0.05
and a power of 80%; 37 patients had to be accrued to observe
26 responses. If less than 12 responses were seen in the first
24 patients, the study should have been discontinued. Re-
sponse analysis was performed for eligible patients only.
Toxicity analysis included all patients. Survival data were
calculated using the Kaplan-Meier method.
RESULTS
Patient Characteristics
Between January 2002 and December 2004, 42 patients
were enrolled (23 male, 19 female; mean age 61.3 years,
range 42-78 years). All patients gave informed consent. Five
patients were ineligible because of stage IV disease in four
patients and stage IIIB disease with pleural effusion in one
patient. Patient characteristics of the eligible patients are
presented in Table 1.
Activity
A total of 102 chemotherapy courses were adminis-
tered, with a median of three cycles per patient (range, one to
four). Two patients with a partial response received four
cycles instead of the planned three because of a delay in the
start of radiotherapy because of logistical problems.
The overall clinical response rate in the 37 eligible
patients was 51% (95% CI, 34%-68%) and for stage IIIA and
IIIB disease 38% (9 of 16) and 61.9% (13 of 21), respec-
tively, with no complete responses. No disease progression
was observed.FIGURE 1. Treatment schedule
TABLE 1. Redosing schedule related to toxicity
Gemcitabine
dose
(mg/m2) WBC  109/L
ANC  109/L
and/or
Platelets  109/L
and/or
1250 2 1 100
1000 1–2 0.5–1 50–100
0 1 0.5 50
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Toxicity and Dose Intensity
Five patients were excluded from the toxicity analysis,
one because of erythropoietin administration and four be-
cause only data from cycle one were available. In the remain-
ing 37 patients, grade 3 to 4 thrombocytopenia was seen in 13
patients (35.1%), with 12 (32.4%) grade 3 and 1 (2.6%) grade
4) (Table 2). Six patients required platelet transfusions, but no
overt hemorrhages were observed. Grade 3 to 4 neutropenia
was observed in 15 (40.5%) of patients: 13 (35.1%) grade 3
and 2 (5.2%) grade 4. No febrile neutropenia occurred. In one
patient (2.6%), a grade 3 anemia was found, but erythrocyte
transfusions were given in 10 patients (27%) (Table 3).
Except for dyspnea, which was found in five patients
(13.2%), non-hematological toxicity was low.
The planned dose intensity was 208 mg/wk for carbo-
platin and 1542 mg/wk for gemcitabine. Relative dose inten-
sity in the 37 patients equaled 99% for carboplatin and 91%
for gemcitabine.
Radiation Therapy
Of the patients who received the planned treatment,
89% (33 of 37) underwent radiotherapeutic treatment. Four
patients did not undergo radiotherapy. One patient died after
chemotherapy before the start of radiation therapy because of
myocardial infarction that was not related to chemotherapy.
One patient had a marginal pulmonary function but was
considered by a radiation oncologist to be fit for involved
field radiotherapy. However, the patient’s clinical condition
deteriorated after chemotherapy, and he was subsequently
judged to be unfit for radiotherapy. In two otherwise fit
patients, the initial radiation fields were considered to be
excessively large for radical radiotherapy, and we planned to
irradiate the post-chemotherapy volume. A lack of response
to chemotherapy led to the decision not to irradiate. These
were the only two patients included in the study for who we
planned to irradiate the post-chemotherapy volume. Mean
dose was 42.5 Gy (range, 20-66 Gy). During and after
radiotherapy, one patient developed grade 3 esophagitis.
Radiation pneumonitis occurred in four patients (grade 1 in
two patients and grade 3 in two patients).
Follow-Up
Median survival of all 37 patients was 13 months. The
Kaplan-Meier survival curve is presented in Figure 2. Cur-
rently 78% of patients have progressed. Median time to
disease progression is 9.1 months.
DISCUSSION
In this phase II study designed to investigate the activ-
ity and safety of the gemcitabine-carboplatin combination as
an induction regimen in sequential chemo-radiation for lo-
cally advanced NSCLC, an overall response rate of 51% was
achieved. Table 4 summarizes the characteristics of the pub-
lished data on the combination of gemcitabine and platinum
in locally advanced NSCLC. Because consolidation treatment
is different among the studies, no valid information on time to
progression can be provided. For the cisplatin-based schemes,
response rates after chemotherapy differ between 40% and
70%. In the earlier studies, gemcitabine-cisplatin was given
in a 4-week schedule. In later studies, this was changed to a
3-week schedule. This was done because of toxicity (mostly
hematological), because of which the gemcitabine on day 15
was often omitted. Only one other study with gemcitabine-
carboplatin used as an induction regimen in locally advanced
NSCLC has been published, with a response rate of 41 %.9
Recent data were presented in the same patient group show-
ing a response rate of 74%.10 In the latter studies, the
induction treatment was followed by concomitant treatment
with chemoradiation.
In the absence of randomized data, no formal compar-
ison can be made between cisplatin- and carboplatin-contain-
ing regimens for induction. It is unlikely that such a trial will
ever be conducted because of the large sample size required
TABLE 2. Patient Characteristics
Characteristic No. of Patients (%)
Male/female 19/18 (51/49)
Age (yr) 61.8 (42–78)
PS 0 14 (38)
PS 1 21 (57)
PS 2 2 (5)
Stage IIIA 16 (43)
Stage IIIB 21 (57)
Values are n(%) or mean (range).
TABLE 3. Hematological toxicity
Grade 3 Grade 4
Anemia 1 (2.7) 0 (0)
Thrombocytopenia 12 (32.4) 1 (2.7)
Leukopenia 9 (24.3) 0 (0)
Neutropenia 13 (35.1) 2 (5.4)
Values are n(%). n  37. FIGURE 2. Survival curve for all 37 eligible patients.
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to demonstrate a true difference. In advanced disease, such
studies have been performed.6,8 In neither of these studies
was a significant difference in response rate between gemcit-
abine cisplatin or gemcitabine carboplatin found. In both
studies, the response rate in the cisplatin arm was higher, but
this did not reach statistical significance.
Toxicity was limited in the study. The known dose-
limiting toxicity of the gemcitabine-carboplatin combination
is hematologic.6 Although thrombocytopenia grade 3 and 4
was present in 35% of cases, this was never associated with
bleeding. Neutropenia grade 3 and 4 was present in 41% of
patients, but no hospitalization because of febrile neutropenia
was necessary. Anemia grade 3 was present in only one
patient, but 10 patients received an erythrocyte transfusion,
which may have influenced this number. Almost all transfu-
sions were given after the completion of the second cycle.
The high number of transfusions in relation to the objective
toxicity numbers may be related to the fact that, in 12% of
patients, grade 3 and 4 dyspnea was scored, which may have
made physicians more prone to give blood transfusions. The
toxicities are comparable to the numbers found in other
studies.6,9,11
Survival of our patients was poor. We believe that this
is related to the patient population included; most of our
patients were stage IIIB. Patients with minimal N2 disease
were included into other study protocols. The recent publi-
cation of Fournel et al.3 also included a large population of
patients with stage IIIB disease, and survival in the sequential
arm was comparable to ours. Similarly, the recent phase III
CALGB study 39801 evaluating two concurrent chemo-ra-
diotherapy schedules reported median survivals of 11.4
months for concurrent chemo-radiotherapy, and 13.7 months
for induction chemotherapy followed by the same concurrent
chemo-radiotherapy scheme.12
In recent years, more and more data on the survival
benefit of concurrent therapy have become available. At the
time of the design of the study, these data were not published.
It is therefore also likely that patients with good performance
status were enrolled in this study. These patients will now
preferably be treated with concurrent chemoradiotherapy.
However, in a large group of patients, with poor performance
status or with comorbid conditions, because of the toxicity of
concurrent therapy, sequential therapy will remain standard
of care. For these patients, the possibility of a lesser toxic
chemotherapeutic agent is of importance, and, in these situ-
ations, carboplatin is preferred.
In conclusion, gemcitabine carboplatin is an active and
safe chemotherapeutic regimen, especially for patients in
whom cisplatin-based chemotherapy is contraindicated.
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